ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly zyprexa (olanzapine) — U.S. revenue ($M) [legacy] ($M)
Quarterly figures from Eli Lilly's filings and investor materials
Latest, Q4 2024
1.50
Period ended Dec 31, 2024
Change on a year earlier
-85.4%
10.3 in Q4 2023
History
28 quarters
Since Q1 2017
Sources
23
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Zyprexa (olanzapine) — U.S. revenue ($M) [legacy] ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2024 | Dec 31, 2024 | 1.50 | -85.4% | Form 10-K (filed 2025-02-19) ↗ |
| Q3 2024 | Sep 30, 2024 | 1.90 | -96.2% | Form 10-Q (filed 2024-10-30) ↗ |
| Q4 2023 | Dec 31, 2023 | 10.3 | +145.2% | Form 10-K (filed 2025-02-19) ↗ |
| Q3 2023 | Sep 30, 2023 | 49.9 | +523.8% | Form 10-Q (filed 2024-10-30) ↗ |
| Q4 2022 | Dec 31, 2022 | 4.20 | -62.8% | Form 10-K (filed 2025-02-19) ↗ |
| Q3 2022 | Sep 30, 2022 | 8 | -38.5% | Form 10-Q (filed 2023-11-02) ↗ |
| Q2 2022 | Jun 30, 2022 | 8.70 | +3.6% | Form 10-Q (filed 2022-08-04) ↗ |
| Q1 2022 | Mar 31, 2022 | 9.60 | +39.1% | Form 10-Q (filed 2022-04-29) ↗ |
| Q4 2021 | Dec 31, 2021 | 11.3 | +145.7% | Form 10-K (filed 2024-02-21) ↗ |
| Q3 2021 | Sep 30, 2021 | 13 | -38.7% | Form 10-Q (filed 2022-11-01) ↗ |
| Q2 2021 | Jun 30, 2021 | 8.40 | -7.7% | Form 10-Q (filed 2022-08-04) ↗ |
| Q1 2021 | Mar 31, 2021 | 6.90 | -38.4% | Form 10-Q (filed 2022-04-29) ↗ |
| Q4 2020 | Dec 31, 2020 | 4.60 | -58.9% | Form 10-K (filed 2023-02-22) ↗ |
| Q3 2020 | Sep 30, 2020 | 21.2 | +89.3% | Form 10-Q (filed 2021-10-27) ↗ |
| Q2 2020 | Jun 30, 2020 | 9.10 | -2.2% | Form 10-Q (filed 2021-08-03) ↗ |
| Q1 2020 | Mar 31, 2020 | 11.2 | +20.4% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2019 | Dec 31, 2019 | 11.2 | +30.2% | Form 10-K (filed 2022-02-23) ↗ |
| Q3 2019 | Sep 30, 2019 | 11.2 | +60.0% | Form 10-Q (filed 2020-10-28) ↗ |
| Q2 2019 | Jun 30, 2019 | 9.30 | -21.2% | Form 10-Q (filed 2020-07-31) ↗ |
| Q1 2019 | Mar 31, 2019 | 9.30 | +5.7% | Form 10-Q (filed 2020-05-01) ↗ |
| Q4 2018 | Dec 31, 2018 | 8.60 | -67.2% | Form 10-K (filed 2021-02-17) ↗ |
| Q3 2018 | Sep 30, 2018 | 7 | -44.4% | Form 10-Q (filed 2019-10-25) ↗ |
| Q2 2018 | Jun 30, 2018 | 11.8 | -9.2% | Form 10-Q (filed 2019-08-02) ↗ |
| Q1 2018 | Mar 31, 2018 | 8.80 | -62.9% | Form 10-Q (filed 2019-05-02) ↗ |
| Q4 2017 | Dec 31, 2017 | 26.2 | – | Form 10-K (filed 2020-02-19) ↗ |
| Q3 2017 | Sep 30, 2017 | 12.6 | – | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2017 | Jun 30, 2017 | 13 | – | Form 10-Q (filed 2018-07-25) ↗ |
| Q1 2017 | Mar 31, 2017 | 23.7 | – | Form 10-Q (filed 2018-04-27) ↗ |
Cite this data
StockData. (2026). Eli Lilly Zyprexa (olanzapine) — U.S. revenue ($M) [legacy] ($M), quarterly Q1 2017–Q4 2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med_zyprexa_us
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.